Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
- Author:
Ajit SOOD
1
;
Kirandeep KAUR
;
Ramit MAHAJAN
;
Vandana MIDHA
;
Arshdeep SINGH
;
Sarit SHARMA
;
Amarender Singh PURI
;
Bhabhadev GOSWAMI
;
Devendra DESAI
;
C. Ganesh PAI
;
Kiran PEDDI
;
Mathew PHILIP
;
Rakesh KOCHHAR
;
Sandeep NIJHAWAN
;
Shobna BHATIA
;
N. Sridhara RAO
Author Information
- Publication Type:Original Article
- From:Intestinal Research 2021;19(2):206-216
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India.
Methods:A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed.
Results:A total of 3,863 patients (mean age, 36.7 ± 13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n = 1,870, 57.9%) were from north, CD was more common in south (n = 348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female = 1.6:1). The commonest presentation of UC was moderately severe (n = 1,939, 60%) and E2 disease (n = 1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n = 229, 36.3%) inflammatory (n = 504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n = 26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south.
Conclusions:The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care.
